Thrive Earlier Detection

About:

Thrive Earlier Detection is a healthcare company that integrates earlier cancer detection into routine medical care.

Website: https://thrivedetect.com/

Twitter/X: ThriveDetect

Top Investors: Perceptive Advisors, Sands Capital Ventures, Invus, T. Rowe Price, Lux Capital

Description:

Thrive is a healthcare company focused on saving lives by making earlier detection of cancer a routine part of medical care. It develops CancerSEEK, a liquid biopsy test that is designed to detect many cancers at earlier stages of the disease. CancerSEEK will serve as the core of Thrive’s integrated cancer information offering. The company was launched in 2019 by Third Rock Ventures, with funding from additional investors Section 32, Casdin Capital, Biomatics Capital, BlueCross BlueShield Venture Partners, The Invus Group, Camden Partners Nexus, Cowin Venture, Exact Sciences, and Gamma3.

Total Funding Amount:

$367M

Estimated Revenue Range:

Less than $1M

Headquarters Location:

Cambridge, Massachusetts, United States

Founded Date:

2019-05-30

Contact Email:

info(AT)thrivedetect.com

Founders:

Bert Vogelstein, Christoph Lengauer, Isaac Kinde, Kenneth Kinzler, Nickolas Papadopoulos

Number of Employees:

101-250

Last Funding Date:

2023-01-01

IPO Status:

Private

© 2025 bioDAO.ai